XenoPort

Discovering and developing therapeutics for neurological diseases

XenoPort (NASDAQ: XNPT) is a biopharmaceutical company focusing on developing on commercializing a portfolio of internally discovered products for neurological disorders. The company's lead product, HORIZANT (gabapentin encarbil), was approved by the FDA in 2011 to treat restless leg syndrome. XenoPort completed its IPO on NASDAQ in 2005.

Status

IPO in 2005 (NASDAQ: XNPT)

Year of Investment

1999

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Palo Alto, California

Website

Social Media